FPA008

BIOLOGICAL2 trials

Sponsors

Five Prime Therapeutics, Inc.

Conditions

HealthyPigmented Villonodular SynovitisRheumatoid ArthritisTenosynovial Giant Cell Tumor

Phase 1

Phase 1 Single and Multiple Dose Study of FPA008 in Healthy Volunteers and Rheumatoid Arthritis Subjects

TerminatedNCT01962337

Five Prime Therapeutics, Inc.Healthy, Rheumatoid Arthritis

Start: 2013-10-31End: 2016-04-30Updated: 2021-12-13

Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor

CompletedNCT02471716

Five Prime Therapeutics, Inc.Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor

Start: 2015-06-30End: 2020-04-30Updated: 2021-08-31

Related Papers

A phase I/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS).

Journal of Clinical Oncology2017-05-2042 citations